Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Change in Accured Expenses of -$5.6 million for Q1 2026, down 142.62% on a QoQ basis from $13.1 million in Q4 2025, and up 76.11% year-over-year from -$3.2 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.6 million for Q1 2026.
- Quarterly Change in Accured Expenses rose 76.11% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.2 million (up 715.15% YoY) and the FY2025 annual result came in at -$4.7 million, down 134.92% from the prior year.
- Change in Accured Expenses was -$5.6 million for Q1 2026 at Aurinia Pharmaceuticals, down from $13.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $17.5 million in Q4 2024 and bottomed at -$23.4 million in Q1 2025.
- A 5-year average of $984000.0 and a median of $462000.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 5931.36% — and 2025, when it plunged 194.92%.
- Aurinia Pharmaceuticals' Change in Accured Expenses stood at $616000.0 in 2022, then plunged by 44.48% to $342000.0 in 2023, then soared by 5007.89% to $17.5 million in 2024, then decreased by 24.88% to $13.1 million in 2025, then slumped by 142.62% to -$5.6 million in 2026.
- Business Quant data shows AUPH's Change in Accured Expenses at -$5.6 million in Q1 2026, $13.1 million in Q4 2025, and -$641000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn | -5.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.59 Mn |
| Mar 31, 2026 | -5.59 Mn |
| Dec 31, 2025 | 13.12 Mn |
| Dec 31, 2025 | 13.12 Mn |
| Sep 30, 2025 | -641,000.00 |
| Sep 30, 2025 | -641,000.00 |
| Jun 30, 2025 | 6.27 Mn |
| Jun 30, 2025 | 6.27 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Mar 31, 2025 | -23.41 Mn |
| Dec 31, 2024 | 17.47 Mn |
| Dec 31, 2024 | 17.47 Mn |
| Sep 30, 2024 | -334,000.00 |
| Sep 30, 2024 | -334,000.00 |
| Jun 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 4.13 Mn |
| Mar 31, 2024 | -7.94 Mn |
| Mar 31, 2024 | -7.94 Mn |
| Dec 31, 2023 | 342,000.00 |
| Dec 31, 2023 | 342,000.00 |